Lilly Japan To Enlarge Domestic Market Share With New Indications
This article was originally published in PharmAsia News
Executive Summary
Eli Lilly Japan KK plans to increase sales in Japan by seeking new indications for its existing pipeline of drugs. The subsidiary of U.S.-based Eli Lilly, the company began the program by filing for Japanese approval of Gemzar (gemcitabine), a non-small cell lung cancer medicine, for treating biliary tract cancer, and its Cialis (tadalafil) erectile dysfunction drug for treating pulmonary hypertension. The firm says seven of the 13 drugs it has in development are new applications for already-approved products. All of the planning is to reach a goal of moving into the ranks of the top 15 pharmaceuticals in the country by 2025, up from its current 23rd place. (Click here for more - a subscription may be required
You may also be interested in...
Biogen Sees Improving Momentum In Slow Leqembi Launch
Sales of the company’s new drugs have a lot of growing to do to make up for older products’ declines, but Biogen highlighted signs of strength for new launches in its Q1 report.
Vivalink Partners With Rett Syndrome Research Trust To Accelerate Research In Rare Disease
Vivalink will provide ECG wearable technology to monitor patients in RSRT’s Vibrant study, which is aimed at assessing autonomic dysfunction in children with Rett syndrome.
Cidara Offloads Rezzayo, Will Focus On Universal Flu Preventative
Cidara conferred global rights to its novel antifungal to marketing partner, Mundipharma, while reacquiring a flu prophylaxis it licensed to J&J in 2021 and gaining $240m in new funding to back development.